PTX 1.30% 3.9¢ prescient therapeutics limited

Wainright Analyst report

  1. 711 Posts.
    lightbulb Created with Sketch. 274
    https://hcwco.bluematrix.com/sellsi...o&[email protected]&source=mail

    Worth a read. One point that really caught my eye is in relation to FDA approval (page 2). Also, while taking valuations with a grain of salt, has a valuation of 16c based on breast cancer (phase 1b results) alone i.e. excludes AML, ovarian and PTX-100

    " Of note, according to positive discussions with the FDA, Prescient is using pCR instead of PFS, which could be a
    valuable endpoint for accelerated approval. There are multiple PI3K and Akt inhibitors in clinical trials; however, preliminary data, literature, and our due diligence suggest that PTX-200 therapy could be successful in HTR BCa, where others have faltered thus far".​
 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
(20min delay)
Last
3.9¢
Change
0.001(1.30%)
Mkt cap ! $31.40M
Open High Low Value Volume
3.9¢ 3.9¢ 3.7¢ $23.65K 615.0K

Buyers (Bids)

No. Vol. Price($)
3 564695 3.8¢
 

Sellers (Offers)

Price($) Vol. No.
4.0¢ 26186 2
View Market Depth
Last trade - 15.59pm 03/07/2024 (20 minute delay) ?
PTX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.